-Prof. Dr. Hermann Requardt to provide strategic guidance on technology and R&D
SHANGHAI, Nov. 16, 2018 /PRNewswire/ — United Imaging Healthcare Co., Ltd. (UIH), an international leader in advanced medical imaging and radiotherapy equipment, today announced the appointment of Hermann Requardt, Ph.D., former Chief Executive Officer of Siemens Healthcare, as its Senior Scientific Advisor. Prof. Dr. Requardt will provide strategic guidance on business, technology and R&D globally. It marks another strategic move by UIH to expand its global presence.
“Prof. Dr. Requardt’s experience running a global enterprise in this industry accelerates our efforts to further expand internationally,” said Dr. Xue Min, Chairman of the Board & Chief Executive Officer at United Imaging. “His breadth and depth of experience – and perspective – will be a catalyst for innovation and development of quality products and services for our global customers.”
Prof. Dr. Requardt is an Honorary Professor of Physics at the Goethe University in Frankfurt, with nearly 40 years of industry experience. Most recently, he served as CEO of Siemens Healthcare from 2009-2015. Prior to that, he was Chief Technology Officer of Siemens AG. He led Siemens Medical Solution’s Magnetic Resonance business – in the 1990s. Prof. Dr. Requardt sits on several academic and industry boards, and provides strategic guidance for public and private life-science institutions and healthcare companies.
“I met a lot of brilliant scientists and innovators at UIH who not only know how to design excellent products but also think out-of-the-box when it comes to positioning imaging equipment in a changing world of healthcare. Their commitment not only to product superiority but also to AI as future standards for a comprehensive diagnostic approach is essential for addressing both, clinical excellence and healthcare economics within an international team approach,” Prof. Dr. Requardt commented.
In the eight years since its inception, UIH’s footprint has grown to cover a complete range of high-end medical imaging, radiotherapy, Internet healthcare and AI-powered medical devices and services, thus laying a solid foundation for setting up partnerships in the innovation ecosystem globally. The company actively collaborates with nearly 100 universities, hospitals and research institutions across the globe to optimize product features, develop clinical applications and pursue visionary technologies with the goal to improve people’s well-being through scientific innovation and development.
In addition to working with Prof. Dr. Requardt, UIH will further develop its U.S. and global expansion activities by presenting a broad portfolio of products and latest innovations at the annual meeting of the Radiological Society of North America (RSNA) and beyond.
ABOUT UIH
United Imaging Healthcare Co., Ltd. (UIH) develops and produces a full portfolio of advanced medical imaging and radiotherapy equipment, and offers medical IT and intelligent solutions. Founded in 2011 and headquartered in Shanghai, the company has subsidiaries and R&D centers across China, U.S., and other parts of the world. The company has more than 3,200 employees, half of whom are researchers. To date, more than 2,700 hospitals worldwide are using UIH products. To learn more, visit https://www.united-imaging.com.
Campaign attempted a Guinness World Records title for the Largest Soap Bubble Making Lesson to Mark Lung Cancer Awareness Month
HONG KONG, Nov. 18, 2018 /PRNewswire/ — To mark Lung Cancer Awareness Month, “A Breath of Hope” Campaign and the Hong Kong Lung Cancer Study Group (HKLCSG) hosted their first Bubble Cruise Carnival to raise awareness of lung cancer, provide important information on treatment options, and inspire hope among lung cancer patients, their families, and Hong Kong people. During the event, more than 250 participants attempted to set a Guinness World Records title for the Largest Soap Bubble Making Lesson – symbolizing how for lung cancer patients, each breath is a celebration of life. In addition, the event raised funds to support lung cancer patients, in order to show support and care from the public.
More than 250 participants attempting to set a Guinness World Records title for the Largest Soap Bubble Making Lesson
“Lung cancer is one of the most common types of cancer, and the leading cause of cancer death globally and in Hong Kong. In 2015, more than a quarter of all cancer deaths in Hong Kong were attributed to lung cancer,” says Dr. Siu-Kie Au, Chairman of Hong Kong Adventist Hospital Foundation’s Cancer Fund. “Today’s Bubble Cruise Carnival helps spark an important dialogue about this disease and provide a source of hope and support to both lung cancer patients and their caregivers.”
To kick off “A Breath of Hope” Bubble Cruise Carnival invited Mr. Su Chung Tai, a four times Guinness World Records holder and renowned bubble performance master, to lead over 250 participants in the Guinness World Record attempt. The same technique used when blowing bubbles – pursed-lip breathing – also helps with managing dyspnea or shortness of breath. Mr. Su wishes to spread hope to more patients through his bubble making lesson, bringing joy and hope to them. For every participant in the world record attempt, “A Breath of Hope” donated HK$100 to the Hong Kong Adventist Hospital Foundation towards cancer patient care.
Representatives from A Breath of Hope campaign, representative from Hong Kong Adventist Hospital Foundation, Halina Tam, Denice Wai, and Su Chung Tai during the opening ceremony (Left to right: Dr. Siu-Kie Au, Dr. Stephen Yau, Dr. Patricia Poon, Dr. Jacky Li, Carol Mui, Halina Tam, Denice Wai, Su Chung Tai)
During the event, Akina Fong, TV and radio program host, hosted a health talk that featured a panel of oncologists and Halina Tam and Denice Wai – notable Hongkongers with a personal connection to lung cancer. The discussion overviewed non-small cell lung cancer and its treatment options including target therapy and immunotherapy.
Dr. Stephen Yau, Clinical Oncologist and council member of HKLCSG, adds, “For many patients with non-small cell lung cancer, a mutation in the epidermal growth factor receptor (EGFR) leads to both an increased risk and increased progression of the disease. Today’s discussion helped convey how understanding their EFGR mutation status can allow patients to be best equipped to select treatment options along with their doctor.”
Akina Fong hosting a health talk on lung cancer with Dr. Siu-Kie Au, Dr. Stephen Yau, and Dr. Jacky Li
In addition to overviewing treatment options, the panel discussed ways to support patients and their psychological needs; and how families and caregivers can cope with stress.
“As physicians, we understand the importance of care not only from a medical perspective – but also from a psychological and support system perspective,” says Dr. Patricia Poon, Clinical Oncologist and council member of HKLCSG. “Today’s event gave an opportunity to reinforce that to ensure the best approach to care for patients – it involves a holistic perspective not only for patients, but their caregivers as well.”
Akina Fong hosting a panel discussion with Dr. Patricia Poon, Halina Tam, and Denice Wai on how to support patients’ psychological needs, and how families and caregivers can cope with stress
The event also featured health consultations and interactive activities including art therapy, DIY workshops and a “thank you tree” for patients to show their appreciation to their doctors, oncologists, nurses, caregivers, family members, or friends.
“Today’s medical advances offer more treatment options with less side effects. Not only are patients living longer, they have a better quality of life,” adds Dr. Jacky Li, Clinical Oncologist and member of HKLCSG. “With the awareness and funds raised from today’s event – we can further bolster the ways that we are supporting lung cancer patients in Hong Kong.”
A Breath of Hope campaign hosting their first Bubble Cruise Carnival during lung cancer awareness month to send hope and support to patients with lung cancer and to raise awareness of lung cancer among HongKongers
Since 2017, “A Breath of Hope – Living with Lung Cancer” has raised public awareness of lung cancer and provided support to patients, their families, and caregivers across Hong Kong with the support of the Hong Kong Lung Cancer Study Group (HKLCSG). The campaign’s efforts both online and offline provide important information, resources, and programs including a lung cancer education website and regular patient events such as Qi Gong breathing workshop, cooking workshop, expressive arts workshop, physical therapy pain management workshop, and carnivals for lung cancer patients. To find out more about the campaign and how you can help, please visit: www.livingwithlungcancer.asia.
About HKLCSG
The Hong Kong Lung Cancer Study Group (HKLCSG) is a charitable institution established in 2003 by a group of oncology specialists. The objectives of the HKLCSG are to promote interest in the knowledge of lung cancer, to facilitate research for improving the knowledge and treatment of lung cancer, and to improve the standard of care for patients with lung cancer.
About “A Breath of Hope – Living with Lung Cancer” Campaign
“A Breath of Hope – Living with Lung Cancer” is a campaign supported by Hong Kong Lung Cancer Study Group (HKLCSG), aimed at raising public awareness of lung cancer and providing support to patients and their families and caregivers. The campaign logo features a dandelion to symbolise life through all challenges and difficulties and sending good wishes. “A Breath of Hope” hosts an educational website that provides information and resources about lung cancer. In the coming months, the campaign will run a series of events to support lung cancer patients and their families and caregivers. To find out more about the campaign and how you can help, please visit: www.livingwithlungcancer.asia
About Hong Kong Adventist Hospital Foundation
Hong Kong Adventist Hospital Foundation (HKAHF) was established in 1999 with a mission to assist and support financially disadvantaged people in need of medical treatment in Hong Kong, China, and Asia. Through its major funds including the Cancer Fund, Eye Fund, Adventist Heart Fund and Children’s Hearing Fund, HKAHF strives to positively impact the community and make life-changing differences in the lives of underprivileged children, adults and the elderly.
Proven anticancer effects of Amtak Baechu cabbage, a crossbred of turnip and Baechu cabbage
Intake of kimchi made with Amtak Baechu cabbage doubles the rate of pancreatic cancer cell inhibition compared with standard kimchi
SEOUL, South Korea, Nov. 16, 2018 /PRNewswire/ — World Institute of Kimchi, which discovers and promotes kimchi’s scientific excellence announces that Kimchi, a major Korean traditional fermented food, “evolves” into cancer-preventing kimchi.
This superfood is made with the world’s first anticancer Baechu cabbage variety with enhanced functions (registered name: Amtak Baechu cabbage) created by Jeil Seed Bio Company in Jeungpyeong, Korea.
Prof. Park, Kun-Young and his team at the Department of Food Science and Biotechnology of Cha University, one of the research team in World Institute of Kimchi in Korea, conducted a cancer cell experiment and found that kimchi made with Amtak Baechu cabbage have anticancer effects against pancreatic cancer and hepatic cancer cells.
The result of the study titled “Beneficial Outcomes of Kimchi Prepared with Amtak Baechu Cabbage and Salting in Brine Solution: Anticancer Effects in Pancreatic and Hepatic Cancer Cells” was published in a recent issue of the Journal of Environmental Pathology, Toxicology and Oncology (Vol. 37, Issue 2, 2018).
The team prepared four different kimchi samples for this study: (1) the standard Baechu cabbage and dry salt treatment method (SK-D); (2) the Amtak Baechu cabbage and dry salt treatment method (AK-D); (3) the standard Baechu cabbage and brine solution treatment method (SK-B); and (4) the Amtak Baechu cabbage and brine solution treatment method (AK-B). The anticancer effects of kimchi were evaluated using human pancreas cancer cells (Capan-2) and human liver cancer cells (HepG2).
Both cancer cells showed a significant increase in cell growth inhibition when exposed to AK-D and AK-B compared with SK-D and SK-B. The inhibition of pancreatic cells (Capan-2 cells) in AK-D and AK-B was more than doubled compared with SK-D and SK-B. It was 1.2 times for HepG2 cells. Overall, the results indicate that kimchi made with Amtak Baechu cabbage and treated with brine solution (AK-B) had a superior anticancer potential.
“Another experiment conducted on mice induced with colorectal cancer showed a noticeably lower incidence of inflammatory diseases and tumor when fed with Amtak Baechu cabbage kimchi compared with the standard kimchi,” said Prof. Park.
A crossbred of turnip and Baechu cabbage, Amtak is the first functional Baechu cabbage in the world created by Jeil Seed Bio Company following 13 years of research. The variety is exported to China, Japan, and Canada.
The development of anti-cancer superfood kimchi has been an ongoing effort for many years in Korea. In 2015, Prof. Hahm, Ki Baik and his team at the Gastroenterology Department of CHA Bundang Medical Center, CHA University developed the world’s first kimchi that is effective in preventing gastric cancer associated with Helicobacter pylori. The anticancer kimchi that they developed includes five additional cancer preventive ingredients (leaf mustard, pear, mushroom, Chinese pepper, and kelp). The result of their study was published on the online issue of Oncotarget on August 17, 2015. Oncotarget is a worldwide bio-medical journal covering research on oncology.
Praising Prof. Park, Kun-Young’s discovery, Ha, Jaeho, a general director of the World Institute of Kimchi says, “Kimchi is a fermented food that is responsible for the health of the Korean people, so much so that people who consume kimchi have no additional need for lactic acid bacteria, dietary fiber, or phytochemicals,” He added, “Kimchi is gaining attention as an anticancer superfood because it is made with vegetables like Baechu cabbage, white radish, leaf mustard, garlic, and pepper, all of which help prevent cancer.”
About World Institute of Kimchi
A government-funded research institute established to perform research and development related to kimchi, to lead national technological innovation, nature and develop the kimchi industry that will boost the national growth. It performs overall research and development related to kimchi, in order to lead national technological innovation and nurture and develop the kimchi industry that will boost the national growth.
-Groundbreaking AI-enabled diagnosis technology is able to detect over 30 medical conditions with high-level accuracy including strokes, Alzheimer’s, Thyroids cancer, Breast cancer, and Joint disease
CHICAGO, Nov. 16, 2018 /PRNewswire/ — This month JLK Inspection will participate in the Radiological Society of North America (RSNA) 2018 in Chicago, presenting its latest AI-based medical image diagnosis system.
AI Hub
The company’s technology assists medical practitioners with detecting and monitoring more than 30 medical conditions, including strokes, Alzheimer’s, prostate cancer, lung cancer thyroids cancer, breast cancer, and joint disease. JLK’s AI-enabled image analysis include those conducted in MRI, CT, X-ray and mammography format, with its technology casting a wide net over various diagnostic techniques.
“We look forward to demonstrating our medical imaging system at RSNA,” JLK Inspection CEO Won Tae Kim says. “We are excited to show how we are able to assist users with quantitative analysis of their medical images at their own convenience.”
These include neural network solvers and libraries with an on-site AI platform providing a real time, seamless connection through a user-friendly interface. This also means the JLK system is stable and interlocks with all other in-hospital systems. They also provide state-of-the-art multi-contrast MRI and multi-modality images.
Not only are JLK’s products created to be simple to use, but they provide objectivity of medical care based on quantitative AI analysis in a streamlined, easy-to-analyze format. For this, JLK Inspection has also developed an AI medical all-in-one platform called AI HUB.
This month, JLK will debut the JBS-01K at RSNA 2018 which already received approval from the Korean FDA as a class III device. The system analyzes brain MRI images and clinical information to detect and present results of ischemic stroke diagnosis for users. The company’s newest medical solution for stroke diagnosis is already in the process of gaining FDA and CE approvals in the U.S. and Europe, respectively.
As a multi-diagnosis solution, the JPC-01K also aims at detecting and diagnosing prostate cancer by automatically detecting the exact location of the cancer, then providing the user with a rapid response and prompt diagnosis. Furthermore, the JPC-01K will also give medical professionals the ability to perform an MR-targeted biopsy while helping reduce risks such as injection, pain, etc.
As a testament to its goals and efforts, JLK has raised over $17M in VC funding to date. The company has also worked hard to ensure numerous patents for their technology have been registered.
The imaging solutions company is planning on going public in the near future, with a set IPO on the KOSDAQ in the second half of 2019. Part of JLK’s current global operations include marketing offices in Silicon Valley and R&D and manufacturing facilities in Seoul, ROK.
Along with heading to RSNA this month, taking place from November 25-30, JLK Inspection will also be present at the International Security Expo (ISE) in London, UK from November 28-29. The company will be attending the conference on behalf of their imaging technology JSS-01K, a security solution that detects storage devices (USB, smartphone, external hdd, and tablet pcs) in security x-ray images.
About JLK Inspection Inc.
JLK Inspection is a Seoul, South Korea-based medical solutions provider specializing in AI-based technology. JLK Inspection is a member company of the K-ICT Born2Global Centre. JLK Inspection’s universal AI platform is created by a combination of big data, experts, and our own unique engines & algorithms. It provides the on-site/real-time service that is seamlessly connected to all systems.
Avrist launches Avrist Prime Protection (APP) which guarantees hospital fees and treatment of clients’ critical illness from the early to the final stage.
Avrist also presents digital-based applications, MyAvrist Application (MAPS) and Agency Portal.
JAKARTA, Indonesia, Nov. 16, 2018 /PRNewswire/ — This era with increasingly modern technology is now affecting the lifestyle of people who need financial planning and protection in every phase of life. Financial security is needed to protect and ensure the future of family members having sufficient funds when an undesirable situation occurs. This fund includes the cost of education, land and house installments, anticipation funds for emergency needs, medical treatment costs, funds to pay the needs of elderly life and the pension fund.
Avrist launches Avrist Prime Protection (APP), MyAvrist Application (MAPS) and Agency Portal.
Makki Ibrahim Kusuma, Director of PT. Avrist Assurance said, “Avrist Prime Protection is expected to be able to answer people’s needs and can be a solution to anticipate the risks of life that may occur in the future so that people can move confidently without worrying. Avrist Prime Protection has a death benefit and maturity benefit in the form of 100% sum assured, a fixed pay period of 5, 10 or 20 years with a fixed premium, as well as various other additional protection benefits. “
To complement the superiority of this product, Avrist also launched two additional benefits (rider) that are specifically developed to increase the strength of APP products, Avrist Medimax + 1 andAvrist Perintis + 1.
“Avrist Medimax + 1 is an additional life insurance product that provides insurance benefits by giving hospital fees reimbursement if the Insured is hospitalized, while Avrist Perintis + 1 is an additional life insurance product that provides benefits if the insured suffers from critical illness from beginning stage,” Makki explained.
Avrist Prime Protection (APP) along with riders Avrist Medimax + 1 and Avrist Perintis + 1 are ready to be marketed through Agency Distribution Channels that placed on Avrist Sales Office in several cities in Indonesia.
To increase the competition and support the agent productivity in the current digitalization era, Avrist also launched its latest digital application, MyAvrist Application (MAPS) and Avrist Agency Portal.
MyAvrist Applications (MAPS) is a digital platform in the Android operating system to facilitate the operational activities of the Agency Sales Force in the field, especially in doing sales, distributing e-brochure and explaining e-illustrations. Prospective policy holders can easier fill out and sign directly on the Life Insurance Application Form and make e-submissions by online, whileAvrist Agency Portal is a supporting tool for the Agency Sales Force in terms of managing information related to customers and their coverage to provide the best service for customers. This portal also provides information to Sales Force to monitor productivity during a certain period. Now, Avrist is also developing a new digital application at this moment — Avrist Customer Portal, as a digital tool to access information onlineintended for Avrist customers.“
“This is one of the digital transformations conduct by Avrist in facing the challenges and competition of the insurance business in today’s digital era. We hope that through this application and portal, the Agency Force will be easier to sell and access information wherever you are in providing the best solution for life insurance needs for Indonesia people,” said Makki finishing his speech.
AboutAvrist
PT. Avrist Assurance (Avrist) is the first joint venture life insurance company in Indonesia that has been established since 1975 under the name of Asuransi Jiwa Ikrar Abadi (AJIA). Avrist Assurance continues to grow into one of the leading life insurance companies that can compete in the life insurance industry in Indonesia. With more than 40 years of experience, Avrist has developed several distribution channels including Agency, Bancassurance, Employee Benefit and Sharia which provides life insurance, accident and health insurance, sharia insurance, credit life insurance and pensions both for individuals and corporations. Avrist present in 23 cities with more than 400 employees, supported with more than 2,000 certified agents and cooperating with more than 850 hospital partners in Indonesia to serve the customers.
In 2010, Avrist partnered with Meiji Yasuda Life Insurance Company, one of the life insurance market leader in Japan with over 130 years of experience. In line with its development, Avrist Assurance now has 3 subsidiaries there are Avrist Pension Fund, PT. Avrist General Insurance, and PT. Avrist Asset Management.
With the vision “One Policy for every household in Indonesia“, Avrist is committed to advance a rewarding life for its customers, business partners and also its employees.
PT. Avrist Assurance are registered and supervised by Otoritas Jasa Keuangan.
For More Information: Corporate Communications PT. Avrist Assurance Gedung World Trade Center II Lt. 7 Jl. Jenderal Sudirman, Jakarta 12920 T: +62 21 5789 8188 E:corcom@avrist.com www.avrist.com
Study by Professor Song, Yeong Ok’s team at Pusan National University
SEOUL, South Korea, Nov. 16, 2018 /PRNewswire/ — World Institute of Kimchi, which discovers and promotes kimchi’s scientific excellence announces that kimchi, a major Korean traditional fermented food, helps significantly lower cholesterol and triglycerides levels in the blood found from an animal study. The same study also suggests that kimchi intake can lead to considerably lower expression of inflammatory cytokine.
The study was conducted by Prof. Song, Yeong Ok and her team at the Department of Food Science and Nutrition and Kimchi Research Institute of Pusan National University, which is one of the longest research teams in World Institute of Kimchi in Korea. For eight weeks, the team fed a high-cholesterol diet with kimchi to an experimental group (10 mice) and the same diet without kimchi to a control group (10 mice). The result of the study titled “Preventative activity of kimchi on high cholesterol diet-induced hepatic damage through regulation of lipid metabolism in LDL receptor knockout mice” was published in a recent issue of the Food Science and Biotechnology. (Vol. 27, Issue 1, 2018).
After eight weeks, the triglycerides level in the kimchi group was 138 mg/dl, which was 33.3% lower compared with the control group (208 mg/dl). Triglycerides help build up LDL cholesterol (bad cholesterol) but facilitates the breakdown of HDL cholesterol (good cholesterol). High triglyceride levels can increase the risks of heart diseases and strokes.
In addition, the total blood cholesterol level of the kimchi group was 1,342 mg/dl, which is 14.4% lower compared with the control group (1,568 mg/dl).
Kimchi intake also contributed to preventing fat from building up in the liver. The hepatic triglyceride and total cholesterol levels in the kimchi group were 26.3% and 38.9% lower respectively compared with the control group.
Kimchi also helped sustain healthy liver function. Levels of AST and ALT, which are indicators of liver damage, were both lower in the kimchi group. Elevated AST and ALT levels are generally associated with damaged liver cells caused by hepatitis, fatty liver, and hepatocirrhosis.
Lower inflammatory cytokine activity was also found in mice fed with kimchi. Inflammation and fat accumulation are closely associated with obesity, arteriosclerosis, fatty liver, and other chronic diseases. Overall, the study found that kimchi improves blood vessel health indicators and helps reduce inflammation.
Previous studies have found that the lactic acid bacteria in kimchi helps lower cholesterol.
Praising Song Young – ok ‘s experiment results, Ha, Jaeho a general director of the World Institute of Kimchi says, “The rich dietary fiber in kimchi cabbage, white radish and so on, which are the main ingredients of kimchi, helps lower cholesterol levels.” He added, “This is why kimchi intake is recommended in Western countries where there is a high prevalence of artery diseases such as cardiovascular disorders.”
About World Institute of Kimchi
A government-funded research institute established to perform research and development related to kimchi, to lead national technological innovation, nature and develop the kimchi industry that will boost the national growth. It performs overall research and development related to kimchi, in order to lead national technological innovation and nurture and develop the kimchi industry that will boost the national growth.
Collaboration to enable large-scale transition from glass slides to digital images for pathology diagnoses across all subspecialties
VISTA, California, Nov. 15, 2018 /PRNewswire/ — Leica Biosystems the cancer diagnostics leader achieved a major digital pathology milestone in its multiyear collaboration with Leeds Teaching Hospitals NHS Trust in the UK. In alignment with the company’s VISION24 initiative, this heralds a revolution in the way that cancer and other diseases can be diagnosed.
Pairing technology, systems, and support from Leica Biosystems with medical and scientific expertise from Leeds, this collaboration has resulted in 100 percent digital conversion of the hospital’s glass slides workflow. Looking ahead, it promises to enable a large-scale transition from glass slides to digital images for clinical diagnoses across all subspecialties. From left to right: Jerome Clavel, Vice President/General Manager of Leica Biosystems Pathology Imaging, Darren Treanor, Consultant Pathologist and Lead for the Digital Pathology Project at Leeds Teaching Hospitals NHS Trust and Sian Gibson, Cellular Pathology & Lab Genetics Service Manager, Leeds Teaching hospital.
Pairing technology, systems and support from Leica Biosystems with medical and scientific expertise from Leeds, the collaboration has resulted in 100 percent digital conversion of the hospital’s glass slides workflow. Looking ahead, it promises to enable a large-scale transition from glass slides to digital images for clinical diagnoses across all subspecialties.
“This positions Leeds as a leader in digital pathology for clinical use,” said Darren Treanor, consultant pathologist and lead for the Digital Pathology Project at Leeds Teaching Hospitals NHS Trust. “In partnership with Leica Biosystems, we have created a template and supporting information for other major medical centers around the world to consider as they make the journey to the digital future of cancer diagnostics.”
Leeds is now scanning its glass slides ramping up to approximately 1,000 per day. Digital slides have the advantage of enabling high resolution enlarged views. They also allow secure sharing with other clinicians even in remote locations for additional consultation.
The ultimate goal of this collaboration is greater lab efficiency and diagnostic confidence in less time for patients. The specific actions taken at Leeds include:
[1] 100% digitization of the slides workflow of the Leeds histopathology lab.
[2] Comprehensive and practical validation process to promote pathologists’ acceptance of digital pathology
[3] Knowledge-sharing through digital pathology workshops attended by more than 55 institutions over the last 18 months and multiple industry publications.
These objectives align with Leica Biosystems’ VISION24 initiative.
“VISION24 reflects Leica Biosystems’ focus on innovation—a future in which clinicians from various specialties work seamlessly together to provide patients with a highly accurate diagnosis, consistently and efficiently, within 24 hours of biopsy,” explained Melissa Aquino, President of Leica Biosystems. “As experts in the workflow from biopsy to diagnosis, we continually innovate to provide the tools and technology, the systems and processes, that will deliver pathology’s great promise to transform cancer diagnostics for the benefit of patients.”
The clinical use claims described in the information provided have not been cleared or approved by the U.S. Food and Drug Administration, nor are the products available in the United States.
About Leica Biosystems Leica Biosystems is a global leader in cancer diagnostics with the most comprehensive portfolio from biopsy to diagnosis. We are committed to delivering Accuracy, Quality and Workflow Efficiencies to help advance diagnostic confidence.
About Leeds NHS Trust Leeds Teaching Hospitals NHS Trust is one of the largest teaching hospitals in Europe, a regional and national cent for specialist treatment, a world-renowned biomedical research facility and a leading clinical trials research unit. This means we have access to some of the U.K.’s leading clinical expertise and the most advanced medical technology in the world. With a £1 billion budget, we provide local and specialist services for our immediate population of 770,000 and regional specialist care for up to 5.4 million people.
SHANGHAI, Nov. 15, 2018 /PRNewswire/ — China’s leading one-stop healthcare ecosystem platform, Ping An Good Doctor (the “Company”, stock code: 1833.HK), announced the Memorandum of Understanding (“MoU”) with Bangkok Dusit Medical Service (BDMS), the largest healthcare network in Thailand on 15 November 2018. The two medical service giants will integrate and exchange their experienced medical resources online and offline, and provide one-stop healthcare services for millions of Chinese patients.
Ping An Good Doctor and Bangkok Dusit Medical Service signed MoU
Established in 1969, BDMS is the largest medical group in Thailand and is also one of the most prestigious hospital networks in the Asia-Pacific region. At the global level, BDMS ranks second among private hospital groups in terms of market capitalization. BDMS owns 46 hospitals located in major cities and locations in Thailand and Cambodia, serving Thai patients and foreign patients from the US, Europe, China, Japan, Korea, the UAE, etc. A total of 17 hospitals in the BDMS network have JCI (Joint Commission International) certificates. Over 10,000 qualified doctors and 8,000 nurses work for BDMS, and many of them are experts in Centers of Excellence which specialize in cancer, heart and brain diseases, trauma and orthopedics.
As the leading one-stop healthcare ecosystem platform in China, Ping An Good Doctor builds a service cycle covering online consultation and medicine to offline visits, utilizing the integration of its 1,000 medical professionals, outside doctors and medical network along with world-class advanced artificial intelligence (AI) technology. As of the end of June, 2018, there were 228 million registered users and the Company’s monthly active users (MAU) reached 48.6 million. Ping An Good Doctor is today the largest mobile medical application in China in terms of user scale.
Medical service standards in Thailand are now on par with the standards in some OECD countries. For some specialized areas, such as IVF, cancer and heart, Thai hospital groups like BDMS provide an outstanding medical service. According to World Daily in Thailand, nearly 10 million Chinese visitors traveled to Thailand in 2017, which was a more than 10% year-on-year growth. One of the main factors for the growth is the high-quality medical services which have helped boost medical tourism in Thailand from the China market.
The Chinese demand for overseas medical services has started to grow in recent years, but there is a lack of organizations that can link patients to overseas medical institutions, which leads to unsatisfactory outcomes.
Through the combination of hundreds of millions of online users’ data from Ping An Good Doctor and advanced offline medical services from BDMS, the collaboration between the two parties will provide a set of integrated solutions. The alliance will provide a reliable and comprehensive overseas consultation process which will improve the standards of medical tourism and set an international medical collaboration model. As a result, Chinese users can benefit from accurate information to choose the best medical plan by using Ping An Good Doctor. The cooperation offers more opportunities to Chinese patients and introduces the option of premium medical tourism to middle-income people. It will also help improve how Chinese patients access advanced medical technology overseas, turning medical care into a “no border” resource.
The strategic cooperation with BDMS is an important step for Ping An Good Doctor in its internationalization strategy. The Company will accelerate its moves into the overseas healthcare market, integrate the international service network, and establish the global healthcare ecosystem together with its partners. At present, the healthcare service network of Ping An Good Doctor covers around 10 countries and regions, including the United States, South Korea, Switzerland and Singapore, and the Company has cooperated with hundreds of hospitals overseas. At the same time, Ping An Good Doctor will assist BDMS to engage deeply into the China market by using its huge user base and rich resources. As a result, the brand influence of both parties will be enhanced by this cooperation.
About Ping An Good Doctor (1833.HK)
Ping An Good Doctor is the leading one-stop healthcare ecosystem platform in China. By combining “mobile health + AI technology”, the Company strives to provide every family with a family doctor, every person with an e-health profile and everyone with a healthcare management plan. Ping An Good Doctor has established a comprehensive, one-stop healthcare ecosystem covering family doctor services, consumer healthcare services, a health mall as well as health management and wellness interaction.
As of the end of June 2018, there were 228 million registered users and the Company’s MAU reached 48.6 million. Ping An Good Doctor is today the largest mobile medical application in China in terms of user scale. Ping An Good Doctor employs more than a thousand medical personnel (Assistant Supervisor Level or above from Class III Grade A Hospitals) in its in-house medical team and contracts with 4,650 renowned external doctors. This in-house medical team, empowered by our proprietary AI technology, provides users with 24 x 7 online consultation services. In our offline partnership network, Ping An Good Doctor collaborates with approximately 3,100 hospitals (including more than 1,200 Class III Grade A hospitals) to provide services such as hospital referral, appointment and inpatient arrangements. Ping An Good Doctor also partners with more than 2,000 healthcare institutions, including physical examination centers, dental clinics, cosmetic surgery institutions and more than 10,000 pharmacy outlets, to provide relevant health and wellness services to our users. By integrating our AI-empowered medical team, external doctors and offline network, Ping An Good Doctor has established a closed-loop healthcare ecosystem which enables our users to enjoy online consultations and online drug purchases, as well as online consultations and offline follow-up treatment, thereby providing convenient, high-quality and efficient family doctor services.
In April 2015, the App “Ping An Good Doctor” was officially launched. In May 2016, the Company completed an A round financing and raised US$500 million. In December 2017, the Company completed the pre-IPO financing from Softbank Vision Fund, during which it raised US$400 million. On 4 May 2018, Ping An Good Doctor became the No.1 listed internet health-tech company in the world when it joined the Hong Kong Stock Exchange, stock code 01833.HK. Our IPO cornerstone investors include Blackrock, Capital Group, GIC, Canada Pension Plan Investment Board, Khazanah Nasional Berhad, Swiss Re and CP Group.
-The Generations, Sponsored by Infinitus, Places Fourth in Its Division
SHENZHEN, China, Nov. 14, 2018 /PRNewswire/ — The 12th China Cup International Regatta, sponsored for the first time by Infinitus (China) Company. Ltd., was held at Daya Bay, Shenzhen, between November 8 and 12, 2018. The Generations, a sailing team also sponsored by Infinitus (China) and established by a member of the Lee Kum Kee Family, won fourth place in the HKPN Division A.
The Generations sets sail at China Cup International Regatta 2018
This year, more than 1,600 seasoned sailors representing some 200 teams from over 30 nations and regions competed in various classes, the most ever for this event. During the five-day competition, sailboats from seven racing divisions competed in four races. The Generations, skippered by Mr. Eddy Lee, a member of the fourth generation of the Lee Kum Kee Family, participated in eight sailing races, including windward/downwind, roundabout /endurance and long-distance.
The Generations sets sail at China Cup International Regatta 2018
Mr. Eddy Lee said that regatta is a positive, healthy, exhilarating sport where one is always challenging oneself, with numerous past masters and unpredictability. The Generations went ahead without any hesitation about the challenge despite the ocean’s mighty waves and currents, demonstrating Lee Kum Kee and Infinitus’ determination in keeping pace with the times and forging ahead in the competitive commercial environment. Participation in such a high-end sporting event was not only a great way to showcase the innovative and enterprising spirit of the brand, but reflective of the corporate spirit “Constant Entrepreneurship”, with an emphasis on business sustainability.
The Generations sets sail at China Cup International Regatta 2018
Last year, the Generations, with Mr. Eddy Lee at the helm, placed well at the China Cup. This year, the Generations continued to ride the wind and waves and captured fourth place, serving as both an inspiration and impetus to always do better. The crew’s performance at the event will encourage Lee Kum Kee and Infinitus to continue to forge ahead amid the fierce competition and adhere to the spirit of constant entrepreneurship, emphasized Mr. Eddy Lee.
About Infinitus (China) Company Ltd. (www.infinitus.com.cn) Infinitus (China) Company Ltd., founded in 1992 and headquartered in Guangzhou China, is a member of LKK Health Products Group. The Company focuses on R&D, production, sales and services of Chinese herbal health products. It has set up 30 branches and 30 service centers together with over 7,000 exclusive stores on the Chinese mainland.
About China Cup International Regatta (www.chncup.com) The China Cup International Regatta was established in 2007. It has been listed on the World Sailing (formerly ISAF) calendar since 2010, and awarded the Asian Regatta of the Year 5 times. As the first international big boat regatta in Chinese history, the China Cup has evolved as the most influential sailing event across the Asia-Pacific region after 11 years’ development.
EVANSVILLE, Ind., Nov. 14, 2018 /PRNewswire/ — On the morning of October 16th in Evansville, Indiana, the Mead Johnson Nutrition campus — now run by consumer health, hygiene and home giant RB — was visited by three special guests: Xiaoxiaobao Mama, Zaozao Wang, and Janice. Together, these women are famous key opinion leaders in the mom & baby industry in China.
The international guests were invited to one of Mead Johnson’s largest R&D centers in the world. For the benefit of interested mothers, their journey was broadcast in real-time on four livestream platforms China including Tmall, Taobao, Suning and Yi Zhi Bo. This marked the first time a US infant-formula brand ever held a livestream dedicated to educating mothers in China about cutting-edge pediatric nutritional science.
The three influencers involved in the “Nourishing the Brain First” live show (From left to right: Zaozao Wang, Xiaoxiaobao Mama, Janice)
The History Wall: A century-old brand boasts a moving story of origin
The visit started at the Mead Johnson History Wall, which details a story dating back over 100 years, when scientific and medical technology lagged far behind where it is today. The first child of E. Mead Johnson, founder of Mead Johnson Nutrition, was born with a congenital heart defect, which affected his feeding and nutrition. The family worked with pediatrician Dr. Abraham Jacobi (recognized today as the father of American pediatrics) who provided them a feeding mixture which saved the baby’s life.
Years later, E. Mead Johnson was inspired by his son’s experience and hoped to help children all over the world achieve a better life. His focus in infant nutrition research to help more babies in need of care has led to the Mead Johnson Nutrition operation of today.
The MJPNI (Mead Johnson Pediatric Nutrition Institute) : Mead Johnson’s century-long dedication to providing babies better nutrition through human milk research
After learning about the company’s origin, the three Chinese influencers found another profound experience at the MJPNI Evansville Technology Center, which is one of several R&D centers that focuses on cutting-edge science. As a global leader in pediatric nutrition research and development, Mead Johnson has applied this cutting-edge pediatric nutrition research to product development since its inception.
In the Evansville R&D center, the scientists shared the story of how MJN studied the levels of the omega-3 fatty acid DHA in global human milk, and then undertook pioneering clinical studies that showed that breastmilk DHA levels impact babies’ brain development and visual acuity. The MJPNI engineers were then able to put this DHA innovation into practice by demonstrating how DHA can be added into infant nutritional products through a trial run in the technology center. The DHA breakthrough from Mead Johnson has since dramatically changed the industry.
Analytical scientist shows the DHA test result to Janice
Mead Johnson has continued to innovate, as evidenced by the monumental introduction of the Milk Fat Globule Membrane (MFGM). Studies found that MFGM contains nearly 200 special lipids and proteins, which play an important role in the brain development of babies, and has positive impact on both the babies’ immune system and intestinal health.
The Sensory Lab: Emphasis on infant formula R&D is embedded in Mead Johnson’s DNA
“Every drop of nutrition in Mead Johnson’s formula contains the effort of researchers,” Xiaoxiaobao Mama said after she finished visiting the sensory lab. “To be an excellent baby formula brand, you can’t ignore the baby’s feeding experience.”
In addition to the nutritional value of the milk powder, sensory feeling is another factor that affects a baby’s nutrition intake. To better understand the mystery around a baby’s senses, Mead Johnson created a sensory lab. “We make the effort to ensure that our products are consistent for babies in terms of three dimensions: taste, smell and feel,” said a Mead Johnson scientist in the sensory lab. “Many people think adults have the same taste preferences as babies. In fact, a fetus has its own taste preferences in utero, which are different from those of adults.”
Xiaoxiaobao Mama performs a sensory test with a scientist
Brand Recognition: Love that can stand the test of time
Built on the true story of a father seeking to save his child, Mead Johnson is acutely aware of how valuable each child is to their family. The three influencers expressed their appreciation for the Mead Johnson work after their journey.
Xiaoxiaobao Mama – “The needs of babies always come first!When I heard that story that MJN produced a batch of special formula according to an individual baby’s needs and saved his life, I know it is not just a slogan at Mead Johnson.”
Janice – “My baby is a devoted user of Mead Johnson products. This company has withstood the test of time as an enterprise that consistently puts the health and safety of babies as its top priority.”
Zaozao Wang – “Life is more significant here than profits.It allows more families around the world to not only experience the professionalism of Mead Johnson, but also the love and warmth of the infant nutrition company.”
